Peptide Research in South Africa: How to Check Status and Sources

Three takeaways

• Registration is a checkable fact, not a marketing word. Under the Medicines and Related Substances Act 101 of 1965, a product intended to “treat, prevent, or alter bodily functions” must be registered with SAHPRA before it can be sold in South Africa [1], and SAHPRA’s database is public.
• A trial listing is not approval, and a parcel is not participation. Trials here run under SAHPRA authorisation and Good Clinical Practice standards, with screening, consent and monitoring [8]; a vial from a seller carries none of that machinery.
• A missing record settles nothing on its own. An empty search result means “not in this record set” — nothing about legality. Take open questions to a registered professional before money moves.

Who does what: the regulator and the professions

South Africa’s medicines regulator is the South African Health Products Regulatory Authority (SAHPRA), an entity of the National Department of Health that assumed the work of the former Medicines Control Council. Its mandate sits in the Medicines and Related Substances Act 101 of 1965 (with the Hazardous Substances Act for radiation-related work), and every decision rests on three pillars: safety, efficacy and quality [4].

Statutory councils govern the professionals: the Health Professions Council of South Africa (HPCSA) registers health professionals — medical practitioners among them — under the Health Professions Act 56 of 1974 and exists, it states, to protect the public [5]. The South African Pharmacy Council (SAPC), established under the Pharmacy Act 53 of 1974, regulates pharmacists, pharmacy support personnel and pharmacy premises [6].

The roles interlock in one line of SAHPRA advice. For the GLP-1 products — the peptide medicines most people encounter — the regulator says use legitimate products only: in original packaging, from licensed manufacturers, “prescribed by registered healthcare professionals” and dispensed by licensed pharmacists [1]. Those pieces must line up.

Finding registered product information

The first stop is SAHPRA’s Registered Health Products Database — the approved and authorised health products that, in SAHPRA’s words, have met its standards [3]. Searchable fields include product name, applicant, active ingredient and registration number:

1. Note the product exactly as sold — name, form (tablet, pen, cream, vial of powder) and strength.
2. Search by product name, then by active ingredient alone — the marketed and registered names can differ [3].
3. Read a hit literally: the number, applicant and status describe one registered product in one form — not every product sold under a similar name.
4. If nothing comes up, re-check spelling and try the ingredient; SAHPRA has posted a notice about data inconsistencies in this database in the past [3].

Example, November 2024: SAHPRA’s position statement records that Ozempic (semaglutide) is registered in South Africa for type 2 diabetes, in specific pre-filled pen presentations — and “NOT registered in South Africa for weight management” — while Mounjaro (tirzepatide) is registered in specific doses for type 2 diabetes and, at that date, had not been placed on its manufacturer’s market [12]. Status attaches to the product, indication and presentations — not to the molecule as a story.

Approval versus trial participation

Registration and trial participation are different doors. A registered product carries a reviewed label; a clinical trial is a study. SAHPRA’s Clinical Trials unit reviews applications to conduct trials and bioequivalence studies here, authorises importation of unregistered medicines for trial purposes, and must approve amendments while a study runs; locally conducted trials follow the South African Good Clinical Practice guidelines, which the regulator describes as covering scientific and ethical standards [8].

Access to unregistered medicines outside trials is also regulated: SAHPRA’s engagement portal describes Section 21 applications by healthcare professionals for named individual or multiple patients [7]. Nothing in the framework resembles a checkout button — a seller offering an unregistered medicine as a simple purchase offers none of the regulated routes.

Retatrutide is the clean illustration: serious trials exist and, as at 13 October 2026, no regulator has approved it — the status is investigational, and we follow the science in Retatrutide Explained. The distinction between approved medicine, trial material and “research use only” labelling is unpacked in Approved Medicines, Clinical Trials and “Research Use Only”.

Questions to ask about a source

SAHPRA concentrates the risk by channel: unregistered peptides come to market through online platforms, social media, gyms and wellness centres, and informal suppliers [1][2]. These are the questions a source should answer without hedging — each maps to an official register:

• Which registered product is this? Exact name, applicant and registration number, verifiable in SAHPRA’s database [3].
• Does it require a prescription — and whose? For GLP-1 medicines: prescribed by a registered healthcare professional, dispensed by a licensed pharmacist [1].
• What form is it in? Registered GLP-1 products are ready-to-use; SAHPRA states that powder forms are not registered and should be treated with caution [1].
• Why is it so cheap? SAHPRA’s guidance: unusually low prices often indicate counterfeit or illegally manufactured products [1].
• Who is this person, professionally? Check the public registers [5][6].

If answers cannot be matched to an official register, that is information — and SAHPRA asks that suspected illegal sales be reported, on its 24-hour hotline, 0800 204 307 [11].

Counterfeit warnings: what the regulator has found

In May 2026 SAHPRA published a notice that it is “seeing an increase in unregistered peptide products being sold online, in gyms, and through informal channels” — and that, not having been evaluated and approved for safety, quality or efficacy, “they can seriously harm your health” [2]. Its peptide public-information page names BPC-157, TB-500, Melanotan II, CJC-1295, Ipamorelin, PT-141, AOD-9604, Selank and Semax among peptides it describes as illegally marketed, lists risks from injection-site infections and hormonal disruption to possible tumour stimulation and unknown long-term effects, and warns against self-administration without medical supervision [1].

On the GLP-1 side, a November 2025 statement describes sellers falsely claiming affiliation with or authorisation by SAHPRA and major retail pharmacies; SAHPRA’s investigations found the sellers were not based in South Africa, goods came by post from China, the shipped products were not identical to those advertised, and no oral GLP-1 solution had been approved for consumption [11]. A year earlier the regulator had recorded “a proliferation of falsified, compounded and substandard” GLP-1 products on websites and social media, and found sites selling unauthorised semaglutide and tirzepatide [12]. Throughout, authority is claimed but not checkable: the database, not the advertisement, is the arbiter.

How to verify a clinical trial

For international trials, including South African sites of global studies, ClinicalTrials.gov is the main registry to search: enter the compound name, open the record, check the sponsor, phase, overall status (recruiting, completed and so on) and the listed locations [10] — a quoted study should have a record behind it.

Trials conducted in South Africa also have their own register: the South African National Clinical Trials Register (SANCTR) gives the public updated information on trials on human participants conducted here — a trial’s purpose, eligibility, location and contacts. Registration has been nationally required since December 2005, by Department of Health notice [9]; SAHPRA’s clinical-trials page points readers to SANCTR [8].

Two cautions. A listing shows a study is happening, not that a product is approved or that results exist; trials sometimes end unpublished. And if a claimed “South African study” appears in neither registry, ask for its SAHPRA authorisation and SANCTR number; if neither materialises, the claim is unverified. How to Read a Peptide Study explains the record, and our glossary defines the labels.

What we don’t know yet

• Whether the specific products sold as “research peptides” carry any SA registration. An empty result says “not in this record set”, not “illegal” — statuses we could not establish remain unestablished.
• Today’s market availability of named medicines. SAHPRA’s November 2024 statement is dated and specific; positions change, and we have not re-established them beyond the listed sources. [12]
• The outcomes of the May 2026 warning — investigations, enforcement or recalls — were not published in the sources we reviewed. [2]
• Independent South African laboratory data on what informally purchased vials actually contain [11]; peer-reviewed local testing falls outside what we reviewed here.

Authoritative resources

• SAHPRA — Peptide Products, Public Information [1]
• SAHPRA — Registered Health Products Database [3]
• SAHPRA — Clinical Trials [8]
• South African National Clinical Trials Register (SANCTR) [9]
• ClinicalTrials.gov [10]
• Professional registers: HPCSA [5], SAPC [6]
• Reporting routes: SAHPRA whistleblower channels and 24-hour hotline 0800 204 307 [11]

For what these rules mean for your situation, a registered pharmacist or practitioner is the practical first stop, and appropriately qualified South African legal advice is the right route for interpretation — this article is a verification workflow, not an adjudication. Put the method alongside our wider reading toolkit in the Evidence Guide, and see what the compounds being marketed actually have behind them in MOTS-c, KPV and topical versus injectable GHK-Cu.

Sources

1. SAHPRA, Peptide Products – Public Information — https://www.sahpra.org.za/peptide-products-public-information
2. SAHPRA Warning About Unregistered Peptide Products, 15 May 2026 — https://www.sahpra.org.za/document/sahpra-warning-about-unregistered-peptide-products-what-you-need-to-know-and-how-to-stay-safe
3. SAHPRA Registered Health Products Database — https://medapps.sahpra.org.za:6006
4. SAHPRA, Who We Are — https://www.sahpra.org.za/who-we-are
5. HPCSA Public Overview — https://hpcsa.co.za/public-overview
6. South African Pharmacy Council — https://www.sapc.za.org
7. SAHPRA portal user manual, Section 21 overview — https://portal.sahpra.org.za/user-manual/_site/s21_overview.html
8. SAHPRA, Clinical Trials — https://www.sahpra.org.za/clinical-trials
9. South African National Clinical Trials Register (SANCTR) — https://sanctr.samrc.ac.za
10. ClinicalTrials.gov — https://clinicaltrials.gov
11. SAHPRA, 11 November 2025 — GLP-1 products sold via social media — https://www.sahpra.org.za/sahpra-warns-the-public-about-glp-1-products-sold-through-social-media-platforms
12. SAHPRA, 8 November 2024 — position on compounded, substandard and falsified GLP-1 products — https://www.sahpra.org.za/sahpras-position-on-glp1-and-gip-glp1-products-that-are-compounded-substandard-and-falsifiedas

FAQ

How do I check whether a specific peptide product is registered in South Africa? Search SAHPRA’s database by product name, then active ingredient, noting the form: status attaches to one presentation, not to look-alike powders [3][1]. Finding nothing is not a ruling about legality — ask a registered professional.

A website says its product is “SAHPRA-approved”. Can I trust that? SAHPRA reported in November 2025 that some sellers were falsely claiming affiliation with or authorisation by it [11]. Check the database yourself, and report suspicious claims via the hotline (0800 204 307) [11].

Does a registered clinical trial mean a product is approved? No. A registry listing records only that an authorised study is happening [8][9] — not approval, and not proof of benefit.

Can this article tell me whether a product or purchase is legal? No — by design. It sets out a verification workflow and cites official sources; what the law requires in a specific situation depends on facts we cannot see. Ask registered professionals for medical questions and appropriately qualified advice for legal interpretation, with the current SAHPRA pages as the reference point.

Suggest a correction